Skip to Content

Franklin Biotechnology Discovery Adv FTDZX

Analyst rating as of
NAV / 1-Day Return
113.30  /  0.33 %
Total Assets
832.6 Mil
Adj. Expense Ratio
0.790%
Expense Ratio
0.790%
Fee Level
Below Average
Longest Manager Tenure
25.20 years
Category
Health
Investment Style
Mid Growth
Min. Initial Investment
100,000
Status
Open
TTM Yield
1.12%
Turnover

Morningstar’s Fund Analysis FTDZX

Will FTDZX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

An expanding universe presents challenges.

Summary

|

Franklin Biotechnology Discovery is overseen by experienced managers, but limited resources and an undifferentiated process earn the fund a Morningstar Analyst Rating of Neutral.

Unlock our full analysis with Morningstar Investor